| Literature DB >> 35889330 |
Yu Zhang1, Guoying Zhang1, Jianya Ling1,2.
Abstract
Pandemics from various viruses make natural organisms face challenges over and over again. Therefore, new antiviral drugs urgently need to be found to solve this problem. However, drug research and development is a very difficult task, and finding new antiviral compounds is desirable. A range of medicinal fungi such as Ganoderma lucidum and Cordyceps sinensis are widely used all over the world, and they can enhance human immunity and direct anti-virus activities and other aspects to play an antiviral role. Medicinal fungi are used as foods or as food supplements. In this review, the species of medicinal fungi with antiviral activity in recent decades and the mechanism of antiviral components were reviewed from the perspectives of human, animal, and plant viruses to provide a comprehensive theory based on better clinical utilization of medicinal fungi as antiviral agents.Entities:
Keywords: antiviral component; antiviral effect; medicinal fungi
Mesh:
Substances:
Year: 2022 PMID: 35889330 PMCID: PMC9322162 DOI: 10.3390/molecules27144457
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Antiviral activities of medicinal fungi and their mechanism of action in human viruses.
| Virus | Chemical Class | Antiviral Agent | Source | Action Mechanism | Reference | |
|---|---|---|---|---|---|---|
| SARS-CoV-2 | Polysaccharide | L-fucose–containing polysaccharides |
| Vitro | [ | |
| Triterpenes, protein |
| Inhibition ACE activity | [ | |||
| Steroid | Antcins |
| ACE2 inhibitory effect | [ | ||
| Polysaccharide | 20% α-glucans |
| Regulating the immune system | [ | ||
| Polysaccharide | Carbosynth-lentinan (50%β-glucan 12%α-glucan) |
| Reduce the level of inflammation in the lung | [ | ||
| Polysaccharide | In-house Lentinan (72%β-glucan) |
| Reduce the level of inflammation in the lung | [ | ||
| Adenosine | Cordycepin(C10H13N5O3) |
| Spike protein inhibitor | [ | ||
| IV | Crude extract | ME, MFs (MF1, MF2 and MF3) |
| Vitro induce the production of cytokines such as TNF-α, which inhibit the growth of virus in vitro. | [ | |
| Pyranone | Phelligridins E, G |
| Vitro neuraminidase inhibitory activity | [ | ||
| Crude extract | Aqueous extract PIW |
| Vitro interfering with the early replication process of the virus | [ | ||
| Crude extract | Lentinus edodes mycelium extract LEM |
| Vitro Inhibit virus entry into host cells activate the immune response through the type I IFN pathway | [ | ||
| Terpenoids | Cryptoporic acid E |
| Vitro | [ | ||
| Crude extract | Water extract |
| Vitro | [ | ||
| Polysaccharide | APS (D-galactose, |
| Vitro | [ | ||
| Crude extract |
| Vivo increased IL-12 expression and greater number of NK cells | [ | |||
| Crude extract |
| Vitro | [ | |||
| Fatty acid | (2Z,4E)-deca-2,4-dienoic acid (DDEA) |
| Reduce the level of inflammation caused by infection with H1N1 | [ | ||
| Polysaccharide | PCP-II (fucose, mannose, glucose and galactose in molar ration of 1.00:1.63:0.16:6.29) |
| Vaccine adjuvant | [ | ||
| Polysaccharide | Mixed polysaccharides (MPs) |
| Enhanced the level of cellular immunity and humoral immunity | [ | ||
| EV71 | Polysaccharide | Neutral polysaccharide having a β-1,6-linked Glcp backbone with 1,3-α-glucan units |
| Vitro Inhibition of VP1 protein expression and genomic RNA synthesis | [ | |
| Polysaccharide | 95%polysaccharides (glucose 79% and mannose 21%) and 5% proteins |
| Vaccine adjuvant | [ | ||
| Triterpenoid | Lanosta-7,9(11),24-trien-3one,15;26-dihydroxy (GLTA) and Ganoderic acid Y (GLTB) |
| Vitro inhibits the replication of the viral RNA replication through blocking EV71 uncoating | [ | ||
| HIV | Adenosine | Cordycepin(C10H13N5O3) |
| Vitro inhibitory activity on HIV-1 reverse transcriptase IC50 8.2 × 10−3 μM | [ | |
| Water extract |
| Vitro inhibitory activity on HIV-1 reverse transcriptase | [ | |||
| Adenosine | L3a(C10H13N5O4), L3b(C20H20O7), L3c(C12H17N5O5) |
| Vitro inhibitory activity on HIV-1 reverse transcriptase | [ | ||
| Lectin | N-terminal amino acid sequence (NSTDISLNHG) |
| Vitro inhibitory activity on HIV-1 reverse transcriptase IC50 10 μM | [ | ||
| Lectin | N-terminal amino acid sequence |
| Vitro inhibitory activity on HIV-1 reverse transcriptase IC50 0.93 μM | [ | ||
| Protein | N-terminal amino acid sequence (AEGTLLGSRA TCESGNSMY) |
| Vitro inhibitory activity on HIV-1 reverse transcriptase | [ | ||
| Protein | N-terminal amino acid sequence(XHPDLFXX) |
| Vitro inhibitory activity on HIV-1 reverse transcriptase | [ | ||
| Hemolysin | N-terminal amino acid sequence (ATNYNKCPGA) |
| Vitro inhibitory activity on HIV-1 reverse transcriptase IC50 1.8 mM | [ | ||
| Ribonuclease | N-terminal amino acid sequence (TPYLDYLAAL QADGPVVPFIRNWEGALSIS) Molecular mass 20 kDa |
| Vitro inhibitory activity on HIV-1 reverse transcriptase | [ | ||
| Crude extract | NGCs and AGCs |
| Vitro inhibitory effects on the attachment of HIV-1 glycoprotein 120 to cluster of differentiation 4 | [ | ||
| Triterpenoid | Ganoderic acid B |
| Vitro inhibitory activity on HIV-1 reverse transcriptase | [ | ||
| Triterpenoid | Ganoderic acid β, lucidumol B, ganodermanondiol, ganodermanontriol, ganolucidic acid A |
| Vitro inhibitory activity on HIV-1 reverse transcriptase | [ | ||
| Triterpenoid | Ganoderiol F and ganodermanontriol |
| Vitro anti-hiv-1 activity with an inhibition concentration of 7.8 μg/mL | [ | ||
| Triterpenoid | Ganoderic acid B, ganoderiol B, ganoderic acid C1, 3b-5a-dihydroxy-6b-methoxyergosta-7,22-diene, ganoderic acid a, ganoderic acid H and ganoderiol A |
| Vitro inhibitory activity on HIV-1 reverse transcriptase | [ | ||
| Polysaccharide | PSP (28% polysaccharide-to-peptide ratio and a composition of 60.23 mg/g beta-1,3/1,6-glucan) |
| Vitro inhibitory activity on HIV-1 reverse transcriptase IC50 6.25 μg/mL | [ | ||
| Laccase | N-terminal amino acid sequence (AGTSHFADL) |
| Vitro inhibitory activity on HIV-1 reverse transcriptase | [ | ||
| Protein | N-terminal amino acid sequence (CQRAFNNPRDDAIRW) molecular mass 27.5 kDa |
| Vitro inhibitory activity on HIV-1 reverse transcriptase | [ | ||
| Lignin | The elemental analysis; C, 44.6%; H, 4.68%; N, 1.74% |
| Vitro | [ | ||
| Water extract | E-P-LEM and LEM |
| Vitro | [ | ||
| HPV | Crude extract | Fruit body powders |
| Vivo | [ | |
| Crude extract | Non-hormonal gel |
| Vivo | [ | ||
| DENV | Conidia | Conidia |
| Vivo activation of the mosquito’s anti-dengue Toll and JAK-STAT pathways | [ | |
| Adenosine | Cordycepin(C10H13N5O3) |
| Vitro inhibition of viral RNA replication | [ | ||
| Crude extract | Hot aqueous extracts, and aqueous soluble extracts | Vitro | [ | |||
| Aqueous extract | Hesperidin |
| Vitro anti-DENV NS2B-NS3 protease activity | [ | ||
| Triterpene | Ganodermanontriol |
| Vitro | [ | ||
| HV | HBV | Crude extract | Crude extract |
| Reduce apoptosis of renal tubular epithelial cells | [ |
| Crude extract | GF-D extract |
| Vitro directly interferes with HBV replication at the level of DNA polymerase | [ | ||
| Polysaccharide | β-glucan with a (1-3)-β-glucose backbone and (1-6)-β-glucose side chains |
| Treat hepatitis caused by HBV | [ | ||
| Polysaccharide | Glucan |
| Modulate both cellular and humoral immune responses | [ | ||
| Crude extract | Co-fermented broth |
| Vitro | [ | ||
| Triterpene | Ganoderic |
| Vitro | [ | ||
| Polysaccharide | LEP-1 |
| Vitro | [ | ||
| HCV | Crude extract | MSCE and LM-lignin |
| Inhibit the entry of HCVpv into cells | [ | |
| Adenosine | Cordycepin(C10H13N5O3) |
| Inhibit HCV RNA replication in vitro inhibit NS5B polymerase activity | [ | ||
| HV | HSV | Protein | N-terminal amino acid sequence (NH2-REQDNAPCGLN-COOH) |
| Vitro and vivo | [ |
| Crude extract | JLS-SO01 |
| Vitro blocks HSV-I replication at the later stage of the virus replication cycle | [ | ||
| Polysaccharide | APBP polysacchride (approximately 40.6%) and protein (approximately 7.80%) carbohydrates molar ratio (C:H:O = 1:2:1) |
| Vitro | [ | ||
| Crude extract | Water-soluble extracts GLhw and GLlw and eight kinds of methanol-soluble extracts GLMe-1-8 |
| Vitro | [ | ||
| Crude extract | Herbal mixture WTTCGE |
| Vivo | [ | ||
| EBV | Adenosine | Cordycepin(C10H13N5O3) |
| Vitro Affect the synthesis of viral proteins by acting on the genes of EBV | [ | |
| Terpenoid | lucidenic acid P, methyl lucidenates P, methyl lucidenates Q |
| Inhibitory effects on Epstein-Barr virus early antigen induction | [ | ||
| Terpenoid | Ganoderic acid A, |
| Vitro | [ | ||
| RSV | Protein | 114 amino acid residues |
| In vivo reduce the viral titers of RSV reducing NF-jB translocation | [ | |
| PV | Crude extract | LeP(β-D-glucan) |
| Vitro | [ | |
| RV | Polysaccharide | Fucose, mannose, glucose and galactose at a molar ratio 1.00:1.63:0.16:6.29. |
| Adjuvant for rabies vaccine | [ | |
| MARV | Polysaccharide | PCP-II (fucose, mannose, glucose and galactose in molar ration of 1.00:1.63:0.16:6.29) |
| Vaccine adjuvant | [ | |
Antiviral activities of medicinal fungi and their mechanism of action in plant and animal viruses.
| Virus | Chemical Class | Antiviral Agent | Source | Action Mechanism | Reference | |
|---|---|---|---|---|---|---|
| Animal viruses | IHNV | Polysaccharide | LNT-I β-(1→3)-glucan backbone with -(1→6)-glucosyl side-branching units glucose, mannose and galactose with the molar ratio of 19.26:1.20:1.00 |
| Vitro directly inactivate virus and inhibit virus replication | [ |
| MDRV | Polysaccharide | HEP glucose (51.02%), galactose (42.24%), mannose (4.5%) and arabinose (2.2%) |
| Vivo improve the number of intestinal mucosal immune-related cells regulate the homing process of muscovy duck lymphocytes | [ | |
| WSSV | Polysaccharide | β-1,3 glucan BG |
| Enhance the immune level of shrimp | [ | |
| FIV | Crude extract | Ethanol extract |
| Vitro FIV reverse transcriptase inhibitory effect | [ | |
| Crude extract | Commercially available compound HELP-TH1 |
| Vitro | [ | ||
| DWV | Crude extract |
| Vivo | [ | ||
| NNV | Protein | Recombined protein rLZ-8 |
| Vivo activate the immune defense | [ | |
| PCV-2 | Polysaccharide | PS (D-glucose, D-xylose, D-galactose, L-fucose, D-mannose, and L-rhamnose at a molar ratio of 5.35:2.67:1:1.19:0.38:0.37) |
| Vaccine adjuvant | [ | |
| PRRSV | CM-H-L-5 |
| Vitro | [ | ||
| Ergosterol | 5α,8α-epidioxy-22E-ergosta6,22-dien-3β-ol |
| Vitro | [ | ||
| Crude extract | Water extract |
| Vitro and vivo inhibited the entry of PRRSV and the synthesis of PRRSV RNA | [ | ||
| PDCoV | Triterpene | Ergosterol peroxide EP |
| Vitro and vivo activate p38/MAPK and NF- κB signal pathways | [ | |
| BoHV-1 | Crude extract | LeP(β-D-glucan) |
| Vitro | [ | |
| NDV | Crude extract | Methanol and n-butanol fractions |
| Vitro antineuraminidase activity | [ | |
| Polysaccharide | GLP |
| Vaccine adjuvant | [ | ||
| Polysaccharide | AAP and sulfated polysaccharide sAAP |
| Vitro | [ | ||
| Polysaccharide | CMP40, CMP50 |
| Vaccine adjuvant | [ | ||
| Plant viruses | TMV | Steroid | Leiwansterols A, B |
| Vitro | [ |
| Polysaccharide | BAS-F acidic polysaccharide contain carbon and hydrogen |
| Completely inhibit leaf infection and no toxic effect | [ | ||
| Polysaccharide | LNT β-(1→3)-linked backbone of d-glucose residues, two β-(1→6)-d-glucosyl residues are attached for everyfive main-chain d-glucose residues |
| Vitro affects the affinity of TMV coat protein to host and activate some defense genes | [ | ||
| GBNV | Crude extract | Mixed culture filtrate | Vitro | [ | ||
Figure 1Medicinal fungi antiviral actions.
Figure 2Antiviral mechanism of medicinal fungi in vivo.
Figure 3The medicinal fungi involved in this review, a–f are Ganoderma lucidum, Shiraia bambusicola, Lentinus edodes, Hericium erinaceus, Cordyceps militaris, Coriolus versicolor, Cordyceps sinensis, Schizophyllum commune, Omphalia lapidescens, Poria cocos, Polyporus umbellatus, Cryptoporus volvatus, Pleurotus citrinopileatus, Auricularia auricula, Flammulina velutipes, Phellinus igniarius, Beauveria bassiana, and Grifola frondose.
Figure 4Medicinal fungi can resist the virus number in this review.